Overview
Compare with Clovis Oncology, MACROGENICS INC or Karyopharm Therapeutics Inc., or pick any stock.
- TickerELTP on OTC1
- IndustryPharmaceutical Preparations1
- HeadquartersNorthvale, New Jersey1
- Incorporated inNJ3
- Business address165 Ludlow Avenue, Northvale, Nj 076473
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
Act of 1984 (the “Drug Price Competition Act”) as well as generic drug products which require ANDAs.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Scheduled Products Manufacturing Fees brought in 48% of the revenue ELITE PHARMACEUTICALS INC /NV/ broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Scheduled Products Manufacturing Fees | $74.8M | $141.5M |
| Indirect Sales to Wholesalers | $34.0M | $82.5M |
| Direct Sales to Wholesalers | $48.0M | $65.3M |
| Unscheduled Products Manufacturing Fees | $7.2M | $6.3M |
| Unscheduled Products Licensing Fees | $1.8M | $594.5K |
| Scheduled Products Licensing Fees | $248.8K | $465.5K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue50¢$73.8M
- Research and development4¢$5.7M
- Other costs8¢$12.5M
- Income tax8¢$11.9M
- Profit30¢$44.9M
Out of $148.9M in revenue.2
Where each dollar of operating cash went, fiscal 2026
- Capital spending4¢$925.6K
- Kept or used elsewhere96¢$22.8M
Out of $23.7M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total revenue | $148.9M | $84.0M |
| Cost of manufacturing | $73.8M | $44.0M |
| Gross profit | $75.0M | $40.1M |
| Research and development | $5.7M | $8.0M |
| General and administrative | $17.6M | $9.0M |
| Non-cash compensation through issuance of stock options | $176.5K | $227.6K |
| Impairment of intangible assets | $847.0K | $1.6M |
| Depreciation and amortization | $1.5M | $1.7M |
| Total operating expenses | $25.9M | $20.5M |
| Income from operations | $49.1M | $19.6M |
| Change in fair value of derivative financial instruments - warrants | $7.9M | -$18.9M |
| Interest expense and amortization of debt issuance costs | -$396.7K | -$772.4K |
| Interest income | $207.9K | $20.9K |
| Other income | $34.5K | |
| Other income (expense), net | $7.7M | -$19.7M |
| Income (loss) before income taxes | $56.8M | -$52.1K |
| Income tax expense | -$11.9M | -$4.3M |
| Net income (loss) | $44.9M | -$4.3M |
| Basic net income (loss) per share | $0.04 | $0.00 |
| Diluted net income (loss) per share | $0.03 | $0.00 |
| Basic weighted average common stock outstanding | 1.1B shares | 1.1B shares |
| Diluted weighted average common stock outstanding | 1.1B shares | 1.1B shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash | $29.8M | $11.3M | |
| Accounts receivable, net of allowance for expected credit losses of $1,441,523 and $387,533 respectively | $59.7M | $29.2M | |
| Inventory | $21.3M | $16.2M | |
| Prepaid expenses and other current assets | $1.3M | $976.4K | |
| Total current assets | $112.1M | $57.7M | |
| Property and equipment, net of accumulated depreciation of $18,100,243 and $17,028,700 respectively | $10.2M | $10.3M | |
| Intangible assets | $4.8M | $5.6M | |
| Finance lease - right-of-use asset, net of accumulated amortization of $984,801 and $508,470, respectively | $1.3M | $1.8M | |
| Operating lease - right-of-use asset | $1.5M | $2.0M | |
| Deferred income tax asset | $7.8M | $18.4M | |
| Restricted cash - debt service for NJEDA bonds | $471.5K | $453.8K | |
| Security deposits | $92.0K | $92.0K | |
| Total other assets | $563.5K | $545.8K | |
| Total assets | $138.3M | $96.4M | |
| Accounts payable | $6.1M | $3.0M | |
| Accrued expenses | $10.2M | $3.8M | |
| Deferred revenue | $5.6K | ||
| Bonds payable, current portion, net of bond issuance costs | $135.8K | $125.8K | |
| Loans payable, current portion | $92.8K | $120.7K | |
| Related party loans payable (Note 8) | $4.0M | ||
| Lease obligation - finance lease, current portion | $378.8K | $363.1K | |
| Lease obligation - operating lease, current portion | $536.4K | $472.4K | |
| Total current liabilities | $17.4M | $11.8M | |
| Bonds payable, net of current portion and bond issuance costs | $651.6K | $787.4K | |
| Loans payable, net of current portion and loan costs | $2.2M | $2.2M | |
| Lease obligation - finance lease, net of current portion | $851.6K | $1.2M | |
| Lease obligation - operating lease, net of current portion | $1.0M | $1.6M | |
| Derivative financial instruments - warrants | $17.3M | $25.2M | $6.3M |
| Total long-term liabilities | $22.0M | $31.0M | |
| Total liabilities | $39.4M | $42.9M | |
| Common Stock; par value $0.001; 1,445,000,000 shares authorized; 1,077,196,442 and 1,068,463,108 shares issued as of March 31, 2026 and March 31, 2025, respectively; 1,077,096,442 and 1,068,363,108 shares outstanding as of March 31, 2026 and March 31, 2025, respectively | $1.1M | $1.1M | |
| Additional paid-in capital | $173.9M | $173.5M | |
| Treasury stock; 100,000 shares as of both March 31, 2026 and March 31, 2025, at cost | -$306.8K | -$306.8K | |
| Accumulated deficit | -$75.8M | -$120.7M | |
| Total shareholders equity | $98.9M | $53.5M | $57.6M |
| Total liabilities and shareholders equity | $138.3M | $96.4M | |
| Allowance for expected credit loss | $1.4M | $387.5K | |
| Accumulated depreciation, property and equipment | $18.1M | $17.0M | |
| Accumulated amortization, finance lease | $984.8K | $508.5K | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.4B shares | 1.4B shares | |
| Common stock, shares issued | 1.1B shares | 1.1B shares | |
| Common stock, shares outstanding | 1.1B shares | 1.1B shares | |
| Treasury stock, shares | 100.0K shares | 100.0K shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash | $29.8M | $11.3M | |
| Accounts receivable, net of allowance for expected credit losses of $1,441,523 and $387,533 respectively | $59.7M | $29.2M | |
| Inventory | $21.3M | $16.2M | |
| Prepaid expenses and other current assets | $1.3M | $976.4K | |
| Total current assets | $112.1M | $57.7M | |
| Property and equipment, net of accumulated depreciation of $18,100,243 and $17,028,700 respectively | $10.2M | $10.3M | |
| Intangible assets | $4.8M | $5.6M | |
| Finance lease - right-of-use asset, net of accumulated amortization of $984,801 and $508,470, respectively | $1.3M | $1.8M | |
| Operating lease - right-of-use asset | $1.5M | $2.0M | |
| Deferred income tax asset | $7.8M | $18.4M | |
| Restricted cash - debt service for NJEDA bonds | $471.5K | $453.8K | |
| Security deposits | $92.0K | $92.0K | |
| Total other assets | $563.5K | $545.8K | |
| Total assets | $138.3M | $96.4M | |
| Accounts payable | $6.1M | $3.0M | |
| Accrued expenses | $10.2M | $3.8M | |
| Deferred revenue | $5.6K | ||
| Bonds payable, current portion, net of bond issuance costs | $135.8K | $125.8K | |
| Loans payable, current portion | $92.8K | $120.7K | |
| Related party loans payable (Note 8) | $4.0M | ||
| Lease obligation - finance lease, current portion | $378.8K | $363.1K | |
| Lease obligation - operating lease, current portion | $536.4K | $472.4K | |
| Total current liabilities | $17.4M | $11.8M | |
| Bonds payable, net of current portion and bond issuance costs | $651.6K | $787.4K | |
| Loans payable, net of current portion and loan costs | $2.2M | $2.2M | |
| Lease obligation - finance lease, net of current portion | $851.6K | $1.2M | |
| Lease obligation - operating lease, net of current portion | $1.0M | $1.6M | |
| Derivative financial instruments - warrants | $17.3M | $25.2M | $6.3M |
| Total long-term liabilities | $22.0M | $31.0M | |
| Total liabilities | $39.4M | $42.9M | |
| Common Stock; par value $0.001; 1,445,000,000 shares authorized; 1,077,196,442 and 1,068,463,108 shares issued as of March 31, 2026 and March 31, 2025, respectively; 1,077,096,442 and 1,068,363,108 shares outstanding as of March 31, 2026 and March 31, 2025, respectively | $1.1M | $1.1M | |
| Additional paid-in capital | $173.9M | $173.5M | |
| Treasury stock; 100,000 shares as of both March 31, 2026 and March 31, 2025, at cost | -$306.8K | -$306.8K | |
| Accumulated deficit | -$75.8M | -$120.7M | |
| Total shareholders equity | $98.9M | $53.5M | $57.6M |
| Total liabilities and shareholders equity | $138.3M | $96.4M | |
| Allowance for expected credit loss | $1.4M | $387.5K | |
| Accumulated depreciation, property and equipment | $18.1M | $17.0M | |
| Accumulated amortization, finance lease | $984.8K | $508.5K | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.4B shares | 1.4B shares | |
| Common stock, shares issued | 1.1B shares | 1.1B shares | |
| Common stock, shares outstanding | 1.1B shares | 1.1B shares | |
| Treasury stock, shares | 100.0K shares | 100.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net income (loss) | $44.9M | -$4.3M |
| Depreciation and amortization | $1.1M | $1.2M |
| Provision for losses on accounts receivable | $1.1M | $151.3K |
| Impairment of intangible assets | $847.0K | $1.6M |
| Amortization of operating leases - right-of-use assets | $470.8K | $433.9K |
| Amortization of finance leases - right-of-use assets | $476.3K | $462.0K |
| Amortization of debt discount - bonds offering costs | $14.2K | $14.2K |
| Loss on asset disposal | $121.5K | |
| Change in fair value of derivative financial instruments - warrants | -$7.9M | $18.9M |
| Deferred tax expense | $10.5M | $3.8M |
| Non-cash compensation through the issuance of employee stock options | $176.5K | $227.6K |
| Accounts receivable | -$31.6M | -$9.9M |
| Inventory | -$5.0M | -$3.3M |
| Prepaid expenses and other current assets | -$356.8K | -$253.7K |
| Security deposits | $2.3K | |
| Accounts payable | $3.1M | $243.3K |
| Accrued expenses | $6.4M | -$1.5M |
| Deferred revenue | -$5.6K | -$13.3K |
| Lease obligations - operating leases | -$472.4K | -$423.3K |
| Net cash provided by operating activities | $23.7M | $7.5M |
| Purchase of property and equipment | -$925.6K | -$1.6M |
| Purchase of intangible assets | -$900.0K | |
| Proceeds from disposition of property and equipment | $125.2K | |
| Net cash used in investing activities | -$925.6K | -$2.4M |
| Payment of bond principal | -$140.0K | -$130.0K |
| Payments of related party loans payable | -$4.0M | |
| Payments on principal on finance lease obligations | -$380.3K | -$336.2K |
| Proceeds from exercise of stock options | $318.8K | $19.3K |
| Loan payments | -$120.7K | -$378.9K |
| Net cash used in financing activities | -$4.3M | -$825.7K |
| Net change in cash and restricted cash | $18.5M | $4.2M |
| Cash paid for interest | $246.1K | $672.4K |
| Cash paid for income taxes | $1.2M | $612.1K |
| Finance directors and officers insurance premium | $198.5K | |
| Recognition of finance lease right of use asset and lease liabilities entered into | $153.9K | |
| Recognition of operating lease right of use asset and lease liabilities entered into | $79.0K |
No quarter-by-quarter statement was filed.
What it owns
What ELITE PHARMACEUTICALS INC /NV/ reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $28.3M2 Mar 31, 2026 | $27.4M2 Mar 31, 2025 | +3.4% |
| Accumulated depreciation | $18.1M2 Mar 31, 2026 | $17.0M2 Mar 31, 2025 | +6.3% |
| Property and equipment, net | $10.2M2 Mar 31, 2026 | $10.3M2 Mar 31, 2025 | −1.4% |
| Finance-lease assets | $1.3M2 Mar 31, 2026 | $1.8M2 Mar 31, 2025 | −26.9% |
| Operating-lease assets (leased space) | $1.5M2 Mar 31, 2026 | $2.0M2 Mar 31, 2025 | −23.5% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finite-lived intangibles, gross | $5.6M2 Mar 31, 2026 | $6.3M2 Mar 31, 2025 | −11.1% |
| Finite-lived intangibles, net | $4.8M2 Mar 31, 2026 | $5.6M2 Mar 31, 2025 | −15.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $21.3M2 Mar 31, 2026 | $16.2M2 Mar 31, 2025 | +30.9% |
| Raw materials | $12.6M2 Mar 31, 2026 | $10.0M2 Mar 31, 2025 | +26.0% |
| Work in process | $3.3M2 Mar 31, 2026 | $1.4M2 Mar 31, 2025 | +129.8% |
| Finished goods | $5.4M2 Mar 31, 2026 | $4.8M2 Mar 31, 2025 | +11.9% |
Properties, in its own words
We own a facility located at 165 Ludlow Avenue, Northvale, New Jersey (“165 Ludlow”) which contains approximately 15,000 square feet of floor space. This real property and the improvements thereon are encumbered by a mortgage in favor of the New Jersey Economic Development Authority (“NJEDA”) as security for a loan through tax-exempt bonds from the NJEDA to Elite. The mortgage contains certain customary provisions including, without limitation, the right of NJEDA to foreclose upon a default by Elite. The NJEDA has declared the payment of this bond to be in default (for more information on the NJEDA Bonds, see Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations; Liquidity and Capital Resources; NJEDA Bonds”). We are currently using the facility as a laboratory, manufacturing, storage, distribution, and office space.
We own a facility located at 135-137 Ludlow Avenue, Northvale, New Jersey (“135 Ludlow”) which contains approximately 35,000 square feet of floor space. This real property and the improvements thereon are encumbered by a mortgage in favor of East West Bank.
The rest of Item 2
In October 2020, the Company entered into an operating lease for office space in Pompano Beach, Florida (the “Pompano Office Lease”). The Pompano Office Lease is for approximately 1,275 square feet of office space, with Elite taking occupancy on November 1, 2020. The Pompano Office includes a three month abatement from November 2020 through February 2021 and had an original term of three years, ending on October 31, 2023. The Pompano Office Lease was extended for one additional year to October 31, 2024. The Pompano Office Lease expired on October 31, 2024.
In October 2024, the Company entered into an operating lease for office space in Pompano Beach, Florida, at a different location than the property related to the Pompano Office Lease (the “Pompano Office 2 Lease”). The Pompano Office 2 Lease is for approximately 1,270 square feet of office space, with the Company taking occupancy on October 1, 2024. The Pompano Office 2 Lease has a term of three years, ending on September 30, 2027.
The Company has entered into a lease agreement for approximately 35,000 square feet of floor space in a building located at 144 Ludlow Avenue, Northvale, New Jersey (the “144 Ludlow Ave. Lease”). The 144 Ludlow Ave. Lease began on January 22, 2024, and has a term of five years. The 144 Ludlow Ave. Lease will expire on December 31, 2028. The lease terms also include a Company option to extend the term by two years.
Properties used in our operation are considered suitable for the purposes for which they are used, at the time they are placed into service, and are believed adequate to meet our needs for the reasonably foreseeable future.
Item 2 of the 10-K filed Jun 29, 2026.4
Leadership
Who has led ELITE PHARMACEUTICALS INC /NV/, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
- Chief executive officerNasrat A. Hakim Aug 21, 2013 to Apr 2, 202414
- Chief executive officerJerry Treppel Jul 16, 2010 to Mar 18, 201415
- Chief executive officerBernard Berk Nov 15, 2006 to Jan 3, 200816
- ChairNasrat A. Hakim Feb 18, 2016 to Feb 18, 201617
- ChairJerry Treppel Jul 16, 2010 to Nov 18, 201515
- ChairBernard Berk Nov 15, 2006 to Jan 3, 200816
- PresidentNasrat A. Hakim Aug 21, 2013 to Apr 2, 202414
- PresidentChris Dick Mar 16, 2011 to Mar 11, 201318
- PresidentBernard Berk Jan 3, 2008 to Jan 3, 200819
- Chief financial officerMark N. Pellegrino May 8, 2023 to May 8, 202320
- Chief financial officerRobert C. J. Chen Jun 3, 2022 to Jul 7, 202221
- Chief financial officerMarc Bregman May 19, 2021 to Jul 7, 202122
- Chief financial officerAshok G. Nigalaye Mar 27, 2012 to Mar 27, 201223
- Chief financial officerCarter Julian Ward Jul 10, 2009 to Feb 27, 201824
- Chief financial officerMark Gittelman May 4, 2006 to May 4, 200625
- Chief operating officerChris Dick Mar 16, 2011 to Mar 11, 201318
Board members and other officers (22)
- Chief Commercial OfficerKirko Kirkov Sep 13, 2022 to now26
- Executive VP of OperationsDouglas Plassche Apr 9, 2015 to now27
- Chief Scientific OfficerAshok G. Nigalaye Nov 5, 2009 to Apr 27, 201528
- Chief Medical OfficerStuart Charles Apfel Jan 9, 2008 to Jan 9, 200829
- Exec VP & Chief Sci. OfficerCharan Behl Mar 10, 2006 to Nov 15, 200630
- Exec. VP of Corp. DevelopmentChris Dick Mar 10, 2006 to Nov 15, 200631
- Board memberEugene M. Pfeifer Apr 25, 2016 to Feb 27, 201832
- Board memberDavis S. Caskey May 4, 2016 to Nov 27, 202333
- Board memberNasrat A. Hakim Aug 21, 2013 to Apr 2, 202414
- Board memberCarter Julian Ward Mar 21, 2012 to Feb 27, 201734
- Board memberJeffrey A. Whitnell Feb 23, 2011 to Nov 27, 202335
- Board memberChris Dick Mar 16, 2011 to Mar 11, 201318
- Board memberAdam Usdan May 4, 2010 to May 26, 201036
- Board memberAshok G. Nigalaye Jun 12, 2009 to Oct 20, 201537
- Board memberJeenarine Narine Jun 12, 2009 to Feb 18, 201638
- Board memberRam Potti Jun 12, 2009 to Apr 27, 201539
- Board memberWoert Melvin H. Van Jan 28, 2008 to Jan 28, 200840
- Board memberJerry Treppel Nov 6, 2008 to Mar 18, 201441
- Board memberBarry H. Dash May 21, 2007 to now42
- Board memberRobert J. Levenson Jul 5, 2007 to Jan 28, 200843
- Board memberEdward Neugeboren Mar 27, 2006 to Mar 27, 200644
- Board memberVeerappan Subramanian Dec 20, 2006 to Dec 20, 200645
Former names
- ELITE PHARMACEUTICALS INC /DE/Sep 28, 1998 to Feb 8, 20123
Timeline
- Aug 13, 20268-K Results of operations; Regulation FD disclosure46
- Aug 11, 20268-K Regulation FD disclosure47
- Aug 10, 20268-K Regulation FD disclosure48
- Aug 4, 20268-K Regulation FD disclosure49
- Jun 29, 20268-K Results of operations; Regulation FD disclosure50
- Jun 23, 20268-K Regulation FD disclosure51
- Jun 15, 20268-K Regulation FD disclosure52
- Jun 1, 20268-K Regulation FD disclosure53
- Apr 2, 20268-K Regulation FD disclosure54
- Feb 17, 20268-K Results of operations; Regulation FD disclosure55
- Feb 11, 20268-K Regulation FD disclosure56
- Nov 14, 20258-K Results of operations; Regulation FD disclosure57
- Aug 21, 2013New chief executive Nasrat A. Hakim becomes CEO14
- Jul 16, 2010New chief executive Jerry Treppel becomes CEO15
- Nov 15, 2006New chief executive Bernard Berk becomes CEO16
Calendar
When it reported results
- Aug 13, 2026Reported quarterly or annual results46
- Jun 29, 2026Reported quarterly or annual results50
- Feb 17, 2026Reported quarterly or annual results55
- Nov 14, 2025Reported quarterly or annual results57
- Aug 14, 2025Reported quarterly or annual results58
- Jun 30, 2025Reported quarterly or annual results59
- Feb 13, 2025Reported quarterly or annual results60
- Nov 14, 2024Reported quarterly or annual results61
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
122 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 66 major events, 23 insider forms, 12 other. The latest 20:
- Sep 10, 20264 PRIMARY DOCUMENT EDGAR
- Aug 13, 20268-K EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 11, 20268-K/A EDGAR
- Aug 10, 20268-K EDGAR
- Aug 4, 20268-K EDGAR
- Jun 29, 20268-K EDGAR
- Jun 29, 202610-K EDGAR
- Jun 23, 20268-K EDGAR
- Jun 15, 20268-K EDGAR
- Jun 1, 20268-K EDGAR
- Apr 14, 2026UPLOAD EDGAR
- Apr 2, 20268-K EDGAR
- Mar 18, 2026CORRESP EDGAR
- Mar 4, 2026UPLOAD EDGAR
- Feb 17, 20268-K EDGAR
- Feb 17, 202610-Q EDGAR
- Feb 11, 20268-K EDGAR
- Jan 13, 20264 EDGAR
- Nov 14, 20258-K EDGAR
The 122 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
7 open-market trades by officers, directors and large owners since October 2021: 2 buys and 5 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Dash Barry HDirector | Buy | 30,000 | $0.29 | $8.7K | Form 4 |
| Oct 2, 2025 | Plassche DouglasEVP Operations | Sale | 800,000 | $0.62 | $496.0K | Form 4 |
| Aug 22, 2025 | ELITE PHARMACEUTICALS INC /NV/EVP Operations | Sale | 500,000 | $0.52 | $260.0K | Form 4 |
| Jul 10, 2025 | Kirkov KirkoChief Commercial Officer | Buy | 16,366 | $0.59 | $9.7K | Form 4 |
| Jul 8, 2025 | Plassche DouglasEVP Operations | Sale | 200,000 | $0.58 | $116.0K | Form 4 |
| Oct 24, 2024 | Plassche DouglasEVP Operations | Sale | 333,932 | $0.51 | $170.3K | Form 4 |
| Oct 23, 2024 | Plassche DouglasEVP Operations | Sale | 800,000 | $0.49 | $392.0K | Form 4 |
From Forms 4 filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Kelleher Financial Advisors | 1,000 | $365 | 0.0% | +500 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How ELITE PHARMACEUTICALS INC /NV/ is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARELITE PHARMACEUTICALS INC /NV/1
- CIK0001053369
- Employer ID (EIN)22-35426364
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
- Incorporated inNevada4
- Fiscal year endsMarch 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address165 Ludlow Avenue, Northvale, NJ 076471
- Phone20175026461
- Shares outstanding1,077,136,442 as of Aug 13, 202613
- Public float$534.0M as of Sep 30, 20254
- AuditorForvis Mazars, LLP, Iselin, NJ PCAOB ID 686; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceJan 30, 19981
- Filings1,221 in all: 4 (415), 8-K (279), 10-Q (75), 4/A (47), 3 (36), UPLOAD (29), 10-K (25), CORRESP (25)1
All 52 form types
SC 13D/A (24), 8-K/A (22), 424B3 (20), DEF 14A (16), CT ORDER (15), DEFA14A (15), SC 13G/A (14), PRE 14A (13), SC 13G (12), 10QSB (10), EFFECT (10), S-3 (10), 10-Q/A (9), SC 13D (9), 5 (7), PRER14A (7), S-8 (7), 10-K/A (6), D (5), S-3/A (5), NT 10-K (4), PREC14A (4), RW (4), S-1 (4), 10KSB (3), 144 (3), 3/A (3), 424B5 (3), REGDEX (3), SB-2/A (3), 424B1 (2), DEFC14A (2), DFAN14A (2), POS AM (2), S-1/A (2), SB-2 (2), 25 (1), 8-A12B (1), 8-A12G (1), ARS (1), DEL AM (1), NT 10-Q (1), PRRN14A (1), S-4 (1)
- Latest filingsAnnual report (10-K) Jun 29, 2026
Quarterly report (10-Q) Aug 13, 2026
Proxy statement (DEF 14A) Apr 29, 2020
Latest 8-K (8-K) Aug 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | ELTP |
From the cover page of the 10-K filed Jun 29, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks ELITE PHARMACEUTICALS INC /NV/ names in Item 1A of its 10-K filed Jun 29, 2026: 49 risks under these headings, as written.4
- Business Related Risks
- The pharmaceutical industry is highly competitive.
- Natural disasters could cause closures of our facilities and disrupt our operations.
- Interruptions in operations at our sole facility could have a material adverse effect on our business.
- We may sell, withdraw or discontinue manufacture of certain products.
- We may fail to successfully identify, develop and commercialize new products.
- As our competitors introduce their own generic equivalents of our generic drug products, our revenues and gross margin from such products generally decline, often rapidly.
- Our operations could be disrupted by failure of our information systems or cyber-attacks.
- Artificial intelligence based platforms may present new risks and challenges to our business.
- Delays in generic product development may result in failure to achieve adequate return on investment.
- Our business is dependent on market acceptance of our products and social and political pressures, including public concern over the abuse of opioids may adversely affect our business.
- Unstable economic conditions may adversely affect our business.
The other 38 risks
- We depend on qualified scientific and technical personnel and our ability to attract and retain such personnel.
- Unsuccessful collaboration or licensing arrangements could limit revenues and product development.
- A substantial portion of our total revenues is expected to be derived from sales of a limited number of products to a limited number of customers.
- We depend to a large extent on third-party suppliers and distributors for the raw materials for our products, particularly the chemical compounds comprising the active pharmaceutical ingredients (“API’s”) that we use to manufacture our products, as well as for certain finished goods.
- We issue price adjustments and other sales allowances to our customers. Although we may establish reserves based on our estimates of these amounts, if estimates are incorrect and the reserves are inadequate, it may result in adjustments to these liabilities that may have a material adverse effect on our financial position and results of operations.
- Financial and Liquidity Risks
- We have identified material weaknesses in our internal control over financial reporting which could, if not remediated, adversely affect our ability to report our financial condition, cash flows and results of operations in a timely and fairly stated manner and/or increase the risk of future misstatements, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
- While we currently qualify as a smaller reporting company under SEC regulations, we cannot be certain, if we take advantage of the reduced disclosure requirements applicable to these companies, that we will not make our stock less attractive to investors. Once we lose smaller reporting company status, the costs and demands placed upon our management are expected to increase.
- Our operating results could fluctuate significantly.
- Our ability to fund and grow operations is uncertain and we may require additional financing to meet objectives.
- There is a risk of impairment of significant intangible assets on our balance sheet.
- GAAP requires estimates, judgments and assumptions which inherently contain uncertainties.
- Legal and Regulatory Risks
- The pharmaceutical industry is heavily regulated which creates uncertainty and substantial compliance costs.
- Disruptions at the FDA, the DEA, the SEC and other government agencies could negatively impact our business.
- Our business may be adversely affected by legislation or healthcare regulatory reform and initiatives.
- Use of generics may be limited through legislative, regulatory or efforts of pharmaceutical companies.
- Our revenues and profits from generic products may decline as a result of changes in regulatory policy.
- New tariffs, evolving trade policy, and geopolitical factors and military conflicts between the US and other countries may adversely affect our business.
- The DEA could limit the availability of active ingredients used in many of our products.
- We received a CRL from the FDA indicating that the SequestOx™ NDA is not ready for approval.
- Regulatory factors may cause us to be unable to manufacture products or face interruptions in our manufacturing process.
- Agreements between branded pharmaceutical companies and generic pharmaceutical companies are facing increased government scrutiny in the United States and Internationally.
- Our reporting and payment obligations under the Medicaid rebate program and other governmental purchasing and rebate programs are complex and may involve subjective decisions. Any determination that we have failed to comply with those obligations could subject us to penalties and sanctions which could have a material adverse effect on our business.
- Investigations and litigation concerning the calculation of average wholesale prices may adversely affect our business
- Litigation and Liability Related Risks
- We may not be able to obtain or maintain adequate insurance coverages.
- Litigation, product liability claims, product recalls, government investigations and other significant legal proceedings are common in the pharmaceutical industry.
- We are subject to various fraud and abuse laws which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Our products contain controlled substances which may subject us to increased litigation risk and regulation.
- Mandatory REMS programs could increase the cost, burden and liability associated with the commercialization of certain products.
- Illegal distribution and third-party sale of counterfeit versions of our products could have a detrimental effect on our reputation and business.
- Our competitors or other third parties may allege that we are infringing upon their IP, forcing us to expend substantial resources in litigation, the outcome of which is uncertain. Any unfavorable outcome of such litigation, including, without limitation, losses related to “at-risk” product launches, could have a material effect our business, financial position and results of operations.
- Intellectual Property Related Risks
- Our ability to protect intellectual property rights and successfully defend against third-party allegations of IP infringement is vital to our business and uncertain.
- Risks Related to our Common Shares
- Dilution from issuance of shares upon exercise of warrants and options or the perception that dilution may occur could cause the price per share of common stock to fall.
- Our common stock is a penny stock, quoted on the OTC bulletin board, with rules in place that could limit trading and liquidity of our shares, increased transaction costs that could adversely affect our price per share.
- Shareholder activism could negatively affect us.
- Our stock price has been volatile.
- Capital raises through sales of securities may cause substantial dilution to existing shareholders.
- Issuance of shares of common or preferred stock could make achieving a change of control more difficult.
- We have no plans to pay regular dividends or conduct share purchases.
Legal proceedings
On August 17, 2023, Elite filed a Paragraph IV certification with its ANDA to generic Oxycontin and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. The parties agreed to a stipulated dismissal of the case and the judge signed the order dismissing the case on June 12, 2026.
Elite’s launch of a generic Oxycontin will depend on approval by the FDA and the outcome of various litigation involving Purdue or the expiry of the patents listed on the Orange Book.
In the ordinary course of business, we may be subject to litigation from time to time. There is no current, pending or, to our knowledge, threatened litigation or administrative action to which we are a party or of which our property is the subject (including litigation or actions involving our officers, directors, affiliates, or other key personnel, or holders of record or beneficially of more than 5% of any class of our voting securities, or any associate of any such party) which in our opinion has, or is expected to have, a material adverse effect upon our business, prospects financial condition or operations. A significant increase in the number of claims or an increase in amounts owing under successful claims could materially adversely affect our business, financial condition, results of operations and cash flows.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARNasrat A. Hakim, Chair
- 18SEC EDGARChris Dick, President
- 19SEC EDGARBernard Berk, President
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32SEC EDGAREugene M. Pfeifer, Board member
- 33SEC EDGARDavis S. Caskey, Board member
- 34SEC EDGARCarter Julian Ward, Board member
- 35SEC EDGARJeffrey A. Whitnell, Board member
- 36SEC EDGARAdam Usdan, Board member
- 37SEC EDGARAshok G. Nigalaye, Board member
- 38SEC EDGARJeenarine Narine, Board member
- 39SEC EDGARRam Potti, Board member
- 40SEC EDGARWoert Melvin H. Van, Board member
- 41SEC EDGARJerry Treppel, Board member
- 42SEC EDGARBarry H. Dash, Board member
- 43SEC EDGARRobert J. Levenson, Board member
- 44SEC EDGAREdward Neugeboren, Board member
- 45SEC EDGARVeerappan Subramanian, Board member
- 46
- 47SEC EDGARRegulation FD disclosure
- 48SEC EDGARRegulation FD disclosure
- 49SEC EDGARRegulation FD disclosure
- 50
- 51SEC EDGARRegulation FD disclosure
- 52SEC EDGARRegulation FD disclosure
- 53SEC EDGARRegulation FD disclosure
- 54SEC EDGARRegulation FD disclosure
- 55
- 56SEC EDGARRegulation FD disclosure
- 57
- 58
- 59
- 60
- 61